IP Library Granted Patent US 12691085
Granted Patent B2
US 12691085 · App. 18/270,005 · Granted Jul 28, 2026

Cancer treatment composition and method

Inventor: Matthew Myntti (St. Augustine, FL)
Assignee: OSARTIS GmbH
A61K31/194A61K33/00A61K45/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12691085
App. No.
18/270,005
Filed
Jun 28, 2023
Granted
Jul 28, 2026
Kind
B2
Art Unit
1627
USPC
514/574
Abstract

A method for selectively or preferentially reducing the amount of Fe ions available to cancer cells involves introducing to an area of the body which contains cancer cells an effective amount of an aqueous, pH buffered composition that includes dissociation products of a soluble weak acid and a salt of a weak acid. When the amount of arriving Fe ions falls below a first threshold, the cancer cell no longer can proliferate. When the amount of arriving Fe ions falls below a second threshold, the cancer cell dies.

Claims (24)

1 . A treatment method involving selectively or preferentially reducing the amount of Fe ions available to cancer cells or pre-cancerous cells, said method comprising introducing to an area of a body which contains such cells an effective amount of a buffered composition that consists of (a) a solvent component that comprises water and (b) a solute component that comprises anions of a soluble weak acid, hydronium ions, and cations of a strong base, said composition having a pH of 6.5 or less.

2 . The method of claim 1 wherein said soluble weak acid is citric acid.

3 . The method of claim 2 wherein said cations of a strong base are alkali metal ions.

4 . The method of claim 1 wherein said composition has an effective solute concentration of at least 0.5 Osm/L.

5 . The method of claim 4 wherein said composition has an effective solute concentration of at least 0.75 Osm/L.

6 . The method of claim 4 wherein said composition has a pH from 3.0 to 6.5.

7 . The method of claim 6 wherein said composition has a pH from 3.2 to 6.0.

8 . The method of claim 7 wherein said composition has a pH from 3.4 to 5.5.

9 . The method of claim 1 wherein said composition has a pH from 3.0 to 6.5.

10 . The method of claim 9 wherein said composition has a pH from 3.2 to 6.0.

11 . The method of claim 10 wherein said composition has a pH from 3.4 to 5.5.

12 . The method of claim 1 wherein said solvent component consists of water.

13 . The method of claim 12 wherein said composition is carried in a vehicle that results in a semi-solid, said composition eluting therefrom to said body area.

14 . The method of claim 1 wherein said solvent component consists of water and no more than 25% (w/v) of one or more organic liquids.

15 . The method of claim 14 wherein said composition is carried in a vehicle that results in a semi-solid, said composition eluting therefrom to said body area.

16 . The method of claim 14 wherein said solute component further comprises an active anti-cancer agent.

17 . The method of claim 16 wherein said composition is carried in a vehicle that results in a semi-solid, said composition eluting therefrom to said body area.

18 . The method of claim 1 wherein each of the following is true:

said soluble weak acid is citric acid,

said cations of a strong base are alkali metal ions,

said composition has an effective solute concentration of at least 0.75 Osm/L, and

said composition has a pH from 3.4 to 5.5.

19 . The method of claim 18 wherein said composition is carried in a vehicle that results in a semi-solid, said composition eluting therefrom to said body area.

20 . The method of claim 18 wherein said solute component is free of surfactants.